The detection of specific TDP-43 peptides able to quantify the pathological fragments of TDP-43 in post mortem ALS brain tissue, offers the opportunity to develop an in vivo assay to measure pathological TDP-43. This would have major diagnostic, stratification and pharmacodynamic biomarker potential. The finding of CTF in cases labelled as AD may reflect the recent identification of a sub-group labelled Limbic-predominant Agerelated TDP-43 Encephalopathy. Published Abstract (Journal of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, volume 20, S1, November 2019) and Poster - 30th International Symposium on ALS/MND, December 4th - 6th, 2019.
Last updated on
Jan 19, 2022
3 min read